Table 3. Blood half lives of radiolabeled VHH.
Fast t½ | Slow t½ | ||||||
VHH | genotype | (min) | (95% C.I.) | % | (min) | % | (95% C.I.) |
99mTc-ni3A | APP/PS1 | 14.71 | (8.65–49.13) | 89.7 | 580 | 10.3 | (101.8–∞) |
Wildtype | ND | ND | ND | ND | |||
99mTc-pa2H | APP/PS1 | 21.89 | (14.24–39.38) | 79.8 | 2562 | 20.2 | (975.0–∞) |
Wildtype | 10.78 | (7.27–20.76) | 87.1 | 5861 | 12.9 | (969.3–∞) | |
DTPA(111In)-pa2H | APP/PS1 | 19.69 | 12.63–44.60 | 100 | - | - | |
Wildtype | 15.83 | 9.30–53.37 | 100 | - | - |
Half lives were determined by fitting a one or a two phase exponential decay model based on blood obtained from both tail vein and cardiac puncture at several time points after intravenous bolus injection of 2 µg radiolabeled VHH in 12–14 month old APP/PS1 mice and wildtype littermates, as depicted in Figure 2. Please note that DTPA(111In)-pa2H was produced without any additional peptide tags.